GPR119 Agonism Revisited: A Novel Target for Increasing β-Cell Mass?

07:00 EST 1st February 2020 | BioPortfolio

Summary of "GPR119 Agonism Revisited: A Novel Target for Increasing β-Cell Mass?"

No Summary Available


Journal Details

This article was published in the following journal.

Name: Endocrinology
ISSN: 1945-7170


DeepDyve research library

PubMed Articles [24669 Associated PubMed Articles listed on BioPortfolio]

Design and biological evaluation of tetrahydropyridine derivatives as novel human GPR119 agonists.

A series of novel tetrahydropyridine derivatives were prepared and evaluated using cell-based measurements. Systematic optimization of general structure G-1 led to the identification of compound 35 (E...

The optimization of xanthine derivatives leading to HBK001 hydrochloride as a potent dual ligand targeting DPP-IV and GPR119.

A series of xanthine compounds derived from the previous hit 20i with modification on the terminal side chain was discovered through ring formation strategy. Systematic optimization of the compounds w...

Glucagon Like Peptide-1 Receptor Agonism Improves Nephrotoxic Serum Nephritis by Inhibiting T Cell Proliferation.

Glucagon like peptide (GLP)-1 analogs such as liraglutide improved albuminuria in patients with type 2 diabetes in large randomized controlled trials. One of the suspected mechanisms is the anti-infla...

Inadequate β-cell mass is essential for the pathogenesis of type 2 diabetes.

For patients with type 1 diabetes, it is accepted among the scientific community that there is a marked reduction in β-cell mass; however, with type 2 diabetes, there is disagreement as to whether th...

Pancreatic Alpha Cell Mass Across Adult Human Lifespan.

To establish pancreatic alpha-cell mass in lean non-diabetic humans over the adult lifespan, performed as a follow up study to beta cell mass across the adult human lifespan.

Clinical Trials [11768 Associated Clinical Trials listed on BioPortfolio]

Effect of Dietary Oils as G-protein-coupled Receptor Agonists on Glucose Tolerance

Agonistic activation of fat metabolite responsive G-protein-coupled receptors (GPCR) has been linked to improved glucose metabolism through increased glucose-stimulated-insulin-secreting (...

A Comparison of the Haemodynamic and Metabolic Effects of Intravenous Glucagon-like Peptide-1, Glucagon and Glucagon-like Peptide-1:Glucagon Co-agonism in Healthy Male Participants

The study seeks to explore the cardiovascular effects of co-agonism at two peptide receptors, GLP-1 and glucagon. Peptides will be intravenously infused, both in isolation, and combination...

Red Cell Mass and Plasma Volume Measurements in Elderly Men and Women With Anemia

The question of whether the hemoglobin concentration itself accurately represents the underlying red cell mass in elderly patients with anemia has not previously been addressed. This quest...

GPR119 Metformin Add-on

A study in type 2 diabetic subjects on stable metformin therapy to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of co-administering single and multiple oral ...

Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma

The purpose of this study is to investigate the safety, side effects, and benefits of tumor- infiltrating lymphocytes (TILs) when they are given with the drug nivolumab. Nivolumab is a typ...

Medical and Biotech [MESH] Definitions

The phenomenon of antibody-mediated target cell destruction by non-sensitized effector cells. The identity of the target cell varies, but it must possess surface IMMUNOGLOBULIN G whose Fc portion is intact. The effector cell is a "killer" cell possessing Fc receptors. It may be a lymphocyte lacking conventional B- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent.

Drug agonism involving selective binding but reduced effect. This can result in some degree of DRUG ANTAGONISM.

Phenomena and pharmaceutics of compounds that bind to the same receptor binding-site as an agonist (DRUG AGONISM) for that receptor but exerts the opposite pharmacological effect.

A mass spectrometry technique using two (MS/MS) or more mass analyzers. With two in tandem, the precursor ions are mass-selected by a first mass analyzer, and focused into a collision region where they are then fragmented into product ions which are then characterized by a second mass analyzer. A variety of techniques are used to separate the compounds, ionize them, and introduce them to the first mass analyzer. For example, for in GC-MS/MS, GAS CHROMATOGRAPHY-MASS SPECTROMETRY is involved in separating relatively small compounds by GAS CHROMATOGRAPHY prior to injecting them into an ionization chamber for the mass selection.

An analytical method used in determining the identity of a chemical based on its mass using mass analyzers/mass spectrometers.

Quick Search

DeepDyve research library

Searches Linking to this Article